Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia | Zendy

Danielle M. Townsley | Zendy; Phillip Scheinberg | Zendy; Thomas Winkler | Zendy; Ronan Desmond | Zendy; Bogdan Dumitriu | Zendy; Olga Rios | Zendy; Barbara Weinstein | Zendy; Janet Valdez | Zendy; Jennifer Lotter | Zendy; Xingmin Feng | Zendy; Marie J. Desierto | Zendy; Harshraj Leuva | Zendy; Margaret Bevans | Zendy; Colin O. Wu | Zendy; André Larochelle | Zendy; Katherine R. Calvo | Zendy; Cynthia E. Dunbar | Zendy; Neal S. Young | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

Author(s) -

Danielle M. Townsley,

Phillip Scheinberg,

Thomas Winkler,

Ronan Desmond,

Bogdan Dumitriu,

Olga Rios,

Barbara Weinstein,

Janet Valdez,

Jennifer Lotter,

Xingmin Feng,

Marie J. Desierto,

Harshraj Leuva,

Margaret Bevans,

Colin O. Wu,

André Larochelle,

Katherine R. Calvo,

Cynthia E. Dunbar,

Neal S. Young

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1613878

Subject(s) - eltrombopag , medicine , cohort , aplastic anemia , regimen , immunosuppression , thrombopoietin receptor , gastroenterology , surgery , thrombopoietin , bone marrow , haematopoiesis , immune thrombocytopenia , stem cell , platelet , genetics , biology

Acquired aplastic anemia results from immune-mediated destruction of bone marrow. Immunosuppressive therapies are effective, but reduced numbers of residual stem cells may limit their efficacy. In patients with aplastic anemia that was refractory to immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically significant increases in blood counts in almost half the patients. We combined standard immunosuppressive therapy with eltrombopag in previously untreated patients with severe aplastic anemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research